A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127)

• G.V. Long,
• R. Gutzmer,
• A. Haydon,
• E. Muñoz Couselo,
• C. Lebbé,
• M. Carlino,
• W. Chow,
• F. Couture,
• P. Lau,
• F. Spagnolo,
• A.J. Alves Wainstein,
• D. Palmieri,
• C. Rojas García,
• G. de Velasco Oria de Rueda,
• I. Mehmi,
• D. Patel,
• A. Shaikh,
• N.R. Chowdhury,
• S. Bathena,
• S. Suryawanshi,
• P. Rutkowski

Affiliations

G.V. Long

Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia

R. Gutzmer

Johannes Wesling Medical Center Minden, Minden, Germany

A. Haydon

The Alfred Hospital, Melbourne, Australia

E. Muñoz Couselo

Hospital Universitario Vall d'Hebron, Barcelona, Spain

C. Lebbé

Hôpital Saint-Louis, Paris, France

M. Carlino

Westmead Hospital, Sydney, Australia

W. Chow

UC Irvine Health, Irvine, CA, United States of America

F. Couture

Hôpital de l'Enfant Jésus, Quebec City, Canada

P. Lau

Sir Charles Gairdner Hospital, Nedlands, Australia

F. Spagnolo

IRCCS Ospedale Policlinico San Martino, Genova, Italy

A.J. Alves Wainstein

Oncologia de Preciso e Personalizada, Santa Efigênia, Belo Horizonte, Brazil

D. Palmieri

Riverina Cancer Care Centre, Wagga Wagga, Australia

C. Rojas García

Bradford Hill Centro de Investigación Clínica, Recoleta, Chile

G. de Velasco Oria de Rueda

Hospital Universitario 12 de Octubre, Madrid, Spain

I. Mehmi

The Angeles Clinic and Research Institute, Los Angeles, CA, United States of America

D. Patel

Bristol Myers Squibb, Princeton, NJ, United States of America

A. Shaikh

Bristol Myers Squibb, Princeton, NJ, United States of America

N.R. Chowdhury

Bristol Myers Squibb, Princeton, NJ, United States of America

S. Bathena

Bristol Myers Squibb, Princeton, NJ, United States of America

S. Suryawanshi

Bristol Myers Squibb, Princeton, NJ, United States of America

P. Rutkowski

Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland